INTERVIEW: Bayer sees solid asian growth after strong year
This article was originally published in Scrip
Executive Summary
Driven mainly by new launches and underlying economic growth, Bayer is bullish over the prospects for its Asia-Pacific pharma business, predicting continued mid-term expansion ahead of the overall market.